Related references
Note: Only part of the references are listed.Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor ACOSOG Z9000 (Alliance) Intergroup Phase 2 Trial
Ronald P. DeMatteo et al.
ANNALS OF SURGERY (2013)
Cutaneous toxicities of RAF inhibitors
Rachael Anforth et al.
LANCET ONCOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance
G. S. Falchook et al.
ONCOTARGET (2013)
Therapeutic Implications of KIT in Melanoma
Michael A. Postow et al.
CANCER JOURNAL (2012)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
Harkanwal Halait et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2012)
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Heikki Joensuu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors
Michael C. Heinrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors
Rachael Anforth et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Updates on the Management of Gastrointestinal Stromal Tumors
Zubin M. Bamboat et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
A Phase 2 Trial of Complete Resection for Stage IV Melanoma Results of Southwest Oncology Group Clinical Trial S9430
Jeffrey A. Sosman et al.
CANCER (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Does Metastasectomy Improve Survival in Patients With Stage IV Melanoma? A Cancer Registry Analysis of Outcomes
Nabil Wasif et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
Scott E. Woodman et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Martine Van Glabbeke
JOURNAL OF CLINICAL ONCOLOGY (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Melanoma from bench to bedside: meeting report from the 6th international melanoma congress
D. E. Fisher et al.
Pigment Cell & Melanoma Research (2010)
Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma
William D. Tap et al.
NEOPLASIA (2010)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
Jason S. Gold et al.
LANCET ONCOLOGY (2009)
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
Ronald P. DeMatteo et al.
CANCER (2008)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Molecular characterization of pediatric gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
CLINICAL CANCER RESEARCH (2008)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
Heikki Joensuu
HUMAN PATHOLOGY (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases
Jerzy Lasota et al.
MODERN PATHOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Results of tyrosine-kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
Ronald P. DeMatteo et al.
ANNALS OF SURGERY (2007)
Outcome of metastatic GIST in the era before tyrosine kinase inhibitors
Jason S. Gold et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF
JY Du et al.
CANCER CELL (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
BJ Druker
ONCOGENE (2002)
Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
AT van Oosterom et al.
EUROPEAN JOURNAL OF CANCER (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Diagnosis of gastrointestinal stromal tumors: A consensus approach
CDM Fletcher et al.
HUMAN PATHOLOGY (2002)
Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom et al.
LANCET (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival
RP DeMatteo et al.
ANNALS OF SURGERY (2000)
Share Paper
